Methods For Aiding In The Diagnosis Of Alzheimer's Disease By Measuring Amyloid-β Peptide (x-≧41) And Tau

Abstract

This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.


Claims
Owners (US)

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Oct 12, 2010
  • Application: Jun 28, 2004
    US US 87995804 A
  • Priority: Jun 28, 2004
    US US 87995804 A
  • Priority: Jun 6, 1995
    US US 46655495 A
  • Priority: Apr 7, 1995
    US US 41900895 A
  • Priority: Nov 14, 1994
    US US 33914194 A

Download Citation


Sign in to the Lens

Feedback